Panic disorder is an anxiety disorder characterized by unexpected panic attacks. It is often associated with situational (agoraphobic) avoidance stemming from fear of further attacks. Epidemiologic studies suggest that panic disorder, with or without agoraphobia, has a lifetime prevalence between 1.5 and 3.0 percent and a familial tendency. It can run a chronic, relapsing course and can produce significant disability and personal distress. Panic disorder is commonly seen in the family practice setting, but it often eludes detection or is misdiagnosed because its clinical presentation mimics that of other medical conditions. A large body of evidence shows that panic disorder responds to various pharmacotherapies and to cognitive and cognitive-behavioral therapies. Early recognition and prompt, appropriate treatment are the keys to managing this disorder effectively.
Identifying Panic Disorder With and Without Agoraphobia
Panic disorder is characterized by the unexpected, "out of the blue" panic attack. A panic attack is defined as a discrete episode of intense symptoms that peak within 10 minutes and primarily involve sympathetic nervous system manifestations. According to criteria given in the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV), a panic attack must include at least four of the symptoms listed in Table 1.
TABLE 1 Symptoms of Panic Attacks
Dizzy, light-headed or unsteady feeling
Fainting Cardiac symptoms
Chest pain or discomfort
Palpitations, heart pounding or tachycardia
Sweating Respiratory symptoms
Shortness of breath
Feeling of smothering or choking Gastrointestinal symptoms
Abdominal distress Psychologic symptoms
Fear of losing control, going crazy or dying Miscellaneous symptoms
Chills or hot flushes
A diagnosis of panic disorder is made if the patient has experienced recurrent, unexpected panic attacks and shows at least one of the following characteristics: (1) persistent concern about having another attack (anticipatory anxiety); (2) worry about the implications of an attack or its consequences (e.g., suffering a catastrophic medical or mental consequence), or (3) a significant change in behavior related to the attacks.
In clinical populations, panic disorder is usually accompanied by agoraphobia. Agoraphobia refers to avoidance behavior motivated by fear of having another panic attack. It may involve activities that patients fear could provoke an attack, situations where escape may not be readily available or routine activities during which patients are not accompanied by a "safe person" whom they believe could help in case of an attack. Table 2 lists common types of agoraphobic fear and avoidance.
TABLE 2 Examples of Activities And Situations that May be Avoided by Patients with Agophobia
Being far away from home Being without the company of a "safe" person Physical exertion that patients believe could provoke a panic
attack Going to places where escape is not readily available (e.g.,
restaurants, theaters, stores, public transportation) Driving Places where embarrassment could be a consequence of suffering
a panic attack (e.g., social gatherings) Ingesting substances that patients believe could provoke panic
(e.g., foods, medicines, alcohol, caffeine)
Clinical Management of Panic Disorder
Patients presenting with panic-like symptoms should receive a thorough initial evaluation that goes beyond assessment of their primary somatic complaints. Areas of initial evaluation are outlined in Table 3. Several authors[3,4] have recommended a specific work-up for these patients to reduce unnecessary assessments. Panic disorder can be treated effectively with pharmacotherapy, cognitive and cognitive-behavioral therapies or a combination of therapies.
TABLE 3 Areas of Evaluation for Patients with Panic Symptoms
Criteria for an unexpected panic attack Agoraphobic avoidance Use of caffeine and other anxiety-provoking substances Substance-use history Medical history to eliminate organic etiology Psychiatric comorbidity (e.g., depression, interpersonal conflicts) Previous assessments and treatments (psychiatric, medical) Family history
The National Institutes of Health Consensus Development Conference on Treatment of Panic Disorder recommends that patients who are diagnosed with panic disorder should be,provided with a description of indicated treatment options and the advantages and disadvantages of each option. Treatment selection should then be made with the patient's input and in consideration of the severity of the presenting complaints, and the patient's specific history and preferences. The following sections outline treatment options for patients with panic disorder and their known advantages and disadvantages. Considerations for selecting treatment also are presented.
Table 4 lists pharmacologic agents used to treat panic disorder and their common therapeutic dosage ranges.
TABLE 4 Drugs Used For Treating Panic Disorder
SSRIs = selective serotonin reuptake inhibitors; MAOIs = monoamine oxidase inhibitors,
Imipramine (Tofranil) is the medication for panic disorder that has been most thoroughly studied, with at least 10 double-blind, placebo-controlled studies supporting its efficacy in the acute treatment of panic disorder. Clomipramine (Anafranil) has shown similar results in several double-blind trials as well. Other tricyclic antidepressants that have shown promise are listed in Table 4.
The onset of therapeutic action for tricyclic antidepressants typically takes three to four weeks. The average length of treatment is approximately six months but depends on several factors, including the efficiency with which panic suppression is achieved and agoraphobic avoidance, if any, is overcome. In obtaining an optimal response, the physician may find it helpful to assess plasma levels. For example, a therapeutic response should be evident at a level greater than 150 mg per ml, (imipramine and desipramine [Norpramin] combined) in patients receiving imipramine.
Approximately one fourth of patients cannot tolerate the side effects of tricyclic antidepressants. Side effects are commonly anticholinergic (constipation, dry mouth, blurred vision and urinary retention), histaminergic (sedation and weight gain) or adrenergic (orthostatic hypotension).
One of the most burdensome adverse effects for patients with panic disorder, who often fear their own bodily sensations, is the "activation syndrome" that occurs on initial titration in approximately 25 to 40 percent of patients. The syndrome often can be mitigated by education, reassurances and initiating a low starting dosage (e.g., 10 mg of imipramine per day), then increasing gradually and flexibly at a rate of approximately 10 mg every two to three days until a dosage of 50 to 75 mg is achieved. An increment of 25 mg every two to four days from that point is usually well tolerated.
Since patients with panic disorder are often very sensitive to side effect symptoms, they may need more reassurance throughout pharmacotherapy than other patients. Physicians should also be aware that a withdrawal syndrome following abrupt cessation of these agents has been described.
Imipramine and clornipramine are considered first-line treatment options for panic disorder. Some advantages and disadvantages of these agents are listed in Table 5.
TABLE 5 Selected Advantages and Disadvantages of Major Treatment Modalities in Patients with Panic Disorder
TCAs = tricyclic antidepressants; SSRIs selective serotonin reuptake inhibitors; MAOIs = monoamine oxidase inhibitors; BZDs = benzodiazepines; CBT = cognitive-behavioral therapy.
Selective Serotonin Reuptake Inhibitors
Although clinical trials have demonstrated the effectiveness of selective serotonin reuptake inhibitors (SSRIs) in treating depression, initial acceptance of these agents for treating panic disorder preceded well-designed studies that supported their efficacy. Controlled studies are confirming that initial enthusiasm.
Fluvoxamine (Luvox) has shown strong improvement rates in several double-blind and placebo-controlled studies of patients requiring acute treatment.[8-11] Initial controlled studies of other SSRIs such as fluoxetine (Prozac), sertraline (Zoloft) and paroxetine (Paxil) are showing promise as well.
Fewer patients drop out of SSRI therapy than tricyclic antidepressant therapy, suggesting that the SSRIs are slightly better tolerated than the tricyclics. Common side effects of SSRIs include sleep disturbance, headaches, gastrointestinal problems and sexual dysfunction. As with tricyclic antidepressants, beginning with a low starting dosage (e.g., 10 mg fluoxetine per day) and then gradually titrating the dosage upward to therapeutic levels may help minimize adverse effects. A withdrawal reaction has occasionally been described with abrupt cessation of SSRI therapy.
The SSRIs are considered appropriate first-line treatment for panic disorder, especially in patients with comorbid depression. Their advantages and disadvantages are summarized in Table 5.
Monoamine Oxidase Inhibitors
The monoamine oxidase inhibitors (MA01s) are known for their effectiveness in treating atypical depression and social phobia, but they also have shown benefit in treating anxiety states, including panic disorder. Phenelzine (Nardil), in particular, has been proved efficacious in both controlled and open trials.[13,14] Reversible inhibitors of monoamine oxidase A-enzyme such as moclobemide and brofaromine (which require no dietary restrictions) have shown promise in initial clinical trials overseas but are not available in the United States.
Side effects of MAOIs include orthostatic hypotension, weight gain, sexual dysfunction and insomnia. When taking any nonspecific irreversible MAOI, patients must maintain a restrictive tyramine-free diet, and hypertensive crisis is risked if adherence to that diet is not, maintained. The MAOIs also introduce a risk for serious drug-drug interactions (e.g., sympathomimetic drugs and meperidine [Demerol]). These risks lead many patients to refuse treatment with MAOIs, and many physicians reserve MAOIs for use in patients who do not respond to other therapies.
Although MAOIs are not regarded as a first-line treatment for panic disorder, they are considered appropriate therapy for patients who do not respond to other first-line agents like tricyclic antidepressants or SSRIs, and for patients with panic disorder accompanied by atypical depression or comorbid social anxiety.6 Advantages and disadvantages of MAOIs are summarized in Table 5.
Large-scale, controlled outcome studies have shown that benzodiazepines are clinically effective in the treatment of panic disorder.[15,16] A unique advantage of the benzodiazepines is their quick onset of action relative to alternative agents (i.e., hours versus weeks), making them the only pharmacotherapeutic option for managing acutely distressed patients. Another advantage of benzodiazepines may be their broader spectrum of anxiolytic action, which extends beyond the suppression of panic attacks to amelioration of generalized anxiety. Benzodiazepines show the most tolerable side effect profile (most commonly sedation) of the antipanic medications, which may account for the routinely lower dropout rate compared with that of the antidepressants.
The principal drawback of benzodiazepines, particularly short-acting medications such as alprazolam (Xanax), involves their ability to produce physical dependency, manifested by a withdrawal syndrome on abrupt discontinuation. Even with gradual tapering, it may be difficult for some patients to discontinue benzodiazepine therapy. The benzodiazepines have also been known to produce interdose rebound anxiety requiring multiple daily dosing.
Although benzodiazepines are considered an appropriate first-line treatment in certain cases of panic disorder (e.g., when rapid symptom relief is needed), discontinuation difficulties have relegated these medications to a second- or third-line consideration. The most common use for benzodiazepines is to stabilize severe initial symptoms until another treatment (e.g., an SSRI or cognitive behavioral therapy) becomes effective.
Benzodiazepines are not indicated for use in patients who have a history of substance abuse or dependence, or as a first-line, sole intervention in patients with comorbid depression. Advantages and disadvantages of benzodiazepines in the treatment of panic disorder are summarized in Table 5.
Several other agents have been studied and have shown poor to mixed results or are undergoing empiric study for the treatment of panic disorder. Table 6[20-27] lists these agents and briefly summarizes the evidence for their efficacy.
Comparative Outcome of Pharmacotherapy
Not all agents indicated for the treatment of panic disorder have been subjected to head-to-head comparison. Meta-analytic techniques, which make use of standardized, "effect size" scores, allow comparisons of acute treatment response on relevant outcome measures across studies. A recent meta-analysis of 32 randomized, prospective, double-blind, placebo-controlled studies of imipramine, domipramme, alprazolam, fluvoxamine, paroxetine and zimelidine found that all of these agents have proved to be superior to placebo. The SSRIs produced an effect size score that was significantly superior to that of imipramine and alprazolam. A trend favoring alprazolam over imipramine was also evident, although the trend did not reach statistical significance. These and other data have led some investigators to suggest that SSRIs are emerging as the drugs of first choice in the treatment of panic disorder.
Cognitive and Cognitive-Behavioral Treatments
Contrary to common clinical practice, existing evidence does not indicate that general, supportive psychotherapy used alone is an appropriate intervention in the treatment of panic disorder. Although a particular form of psychotherapy called emotion-focused treatment has shown initial promise in a recent empiric study, it warrants further, controlled study before it can be recommended as an evidence-based treatment option for panic disorder.
Cognitive and cognitive-behavioral therapies have received strong empiric support through numerous controlled clinical trials and are the psychotherapeutic treatments of choice for patients with panic disorder. With few exceptions, acute treatment improvement rates associated with these therapies range from 80 to 90 percent of patients.
The major components of cognitive-behavioral therapies are outlined in Table 7.
TABLE 7 Principal Components of Cognitive-Behavioral Therapy in Patients with Panic Disorder
Education about the onset and development of panic disorder and agoraphobia Training in symptom management skills for anxiety, including
training in relaxation methods and diaphragmatic breathing Cognitive restructuring to change thought processes that initiate
and maintain panic attacks and agoraphobic fears and avoidance behavior Exposure simulations involving the attempted induction of
bodily sensations feared by patients with panic disorder Situational exposure aimed at eliminating agoraphobic avoidance behavior
Earlier behavior treatments tended to emphasize situational exposure aimed at reducing agoraphobic avoidance, rather than the panic attacks themselves. Newer treatments target both. Recent meta-analyses of cognitive-behavioral therapy quote an effect size (0.68) that compares favorably with those of pharmacotherapy (0.47) and combined treatments (0.56). Although various approaches to cognitive-behavioral therapy are available, those involving cognitive restructuring and exposure in vivo to feared stimuli have yielded the strongest effect sizes (effect size: 0.88) in meta-analyses.
A recent review of long-term studies reported that approximately 75 percent of treated patients remained improved years after treatment had ended.
Advantages and disadvantages of cognitive-behavioral therapy are summarized in Table 5.
Debate continues about whether panic disorder should be treated initially with cognitive therapy or cognitive-behavioral therapy, pharmacotherapy or a combined approach. Although acute treatment effect sizes may vary between treatment options, physicians and patients must consider several factors that go beyond success rates in acute treatment when selecting treatment. These decisions involve weighing the advantages and disadvantages of each treatment option and how well the options match the patient's presentation, preferences, and personal and financial resources. Although treatment selection guidelines vary, some considerations can be offered.
Regarding the choice of pharmacologic treatment, an evidenced-based approach suggests that the SSRIs are an appropriate first consideration. Although tricyclic antidepressants show similar success rates for acute treatment, their side-effect burden has been greater than that of SSRIs. A high-potency benzodiazepine given at the minimum therapeutic dose may be a useful adjunct to antidepressant therapy if prompt relief is indicated. However, the treatment plan should include discontinuing the benzodiazepine when the antidepressant's maximal effects are expected (i.e., approximately four to six weeks), to minimize the risks of discontinuation difficulties associated with the benzodiazepines. Although benzodiazepines are considered an appropriate intervention after SSRIs and tricyclic antidepressants have failed, they should not be prescribed if a history of or current comorbid substance abuse is suspected or if the patient shows comorbid depression. MAOIs are also an appropriate consideration when comorbid depression or social phobia is evident, although they remain a second choice given the risks they pose.
Cognitive-behavioral therapy is an appropriate first-line consideration in patients with mild to moderate panic disorder or panic disorder with situational avoidance. Although benzodiazepines can be combined temporarily with cognitive-behavioral therapy for prompt relief of severe symptoms, they have been known to interfere with cognitive-behavioral therapy, so their adjunctive use should be minimized. In situations where severe agoraphobic avoidance precludes participation in cognitive-behavioral therapy, consideration should be given to the combined use of SSRI or tricyclic antidepressant pharmacotherapy with cognitive-behavioral therapy. Cognitive-behavioral therapy has also been effective in patients who do not respond to pharmacotherapy and can be used in this role as well.
Acute relapse is common when pharmacotherapy for panic disorder is discontinued. Since recent studies have shown that cognitive-behavioral therapy can effectively reduce discontinuation and relapse difficulties associated with the discontinuation of pharmacotherapy, its adjunctive use with any pharmacotherapy should be considered to help reduce these risks. Other considerations for selecting a first-line treatment include the patient's preference for an approach that includes medication versus one that does not, as well as the availability of cognitive-behavioral treatment in the community.
Once treatment is selected, patients should be monitored periodically. When stabilized, patients should be encouraged to reenter previously avoided situations gradually, regardless of the treatment approach being used. If the treatment response is inadequate after approximately eight weeks of therapy, alternatives should be reconsidered.
Finally, patients with panic disorder often need sensitive clinical management. Many of these patients have been ill for several years and tend to have a history of varied, ineffective and failed treatments. Establishing a therapeutic alliance with patients, as described in Table 8, is an important aspect of any treatment selected.
TABLE 8 Establishing a Therapeutic Alliance in the Treatment of Patients with Panic Disorders
Establish a therapeutic relationship by providing the
following: respectful attention to patient's concerns,
realistic reassurance and instillation of hope, and a
willingness to be available in case of unexpected problems. Provide the patient with some knowledge about panic
disorder (e.g., it is common, it is not life-threatening, it
is treatable). Discuss the components of panic disorder (panic attacks,
anticipatory anxiety and avoidance) and how treatment targets
changes in each component. Explore and discuss patient's concerns about medications. Explain treatment options and their advantages and disadvantages.
[1.] American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, D.C.: American Psychiatric Association, 1994.
[2.] Katon W. Panic disorder: relationship to high medical utilization, unexplained physical symptoms, and medical costs. J Clin Psychiatry 1996;57(Suppl 10):11-8.
[3.] United States Department of Health and Human Services, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, National Institute of Mental Health. Panic disorder in the medical setting. Rockville, Md.: Government Printing Office, 1989; DHHS publication no. (ADM) 89-1629.
[4.] Ballenger JC. Panic disorder in the medical setting. J Clin Psychiatry 1997;58(Suppl 2):13-7.
[5.] Wolfe B, Maser JD. Treatment of panic disorder: a consensus development conference. Washington, D.C.: American Psychiatric Press, 1994.
[6.] Jefferson JW. Antidepressants in panic disorder. J Clin Psychiatry 1997;58(Suppl 2):20-4.
[7.] Kessel JB, Simpson GM. Tricyclic and tetracyclic drugs. In: Kaplan HI, Sadock BJ, eds. Comprehensive textbook of psychiatry. 6th edition. Baltimore: Williams & Wilkins, 1995.
[8.] Black DW, Wesner R, Bowers W, Gabel J. A comparison of fluvoxamine, cognitive therapy, and placebo in the treatment of panic disorder. Arch Gen Psychiatry 1993;50:44-50.
[9.] den Boer JA, Westenberg HG, Kamerbeek WD, Verhoeven WM, Kahn RS. Effect of serotonin uptake inhibitors in anxiety disorders; a double-blind comparison of clomipramine and fluvoxamine. Int Clin Psychopharmacol 1987;2:21-32.
[10.] Hoehn-Saric R, McLeod DR, Hipsley PA. Effect of fluvoxamine on panic disorder. J Clin Psychopharmacol 1993;13:321-6.
[11.] de Beurs E, van Balkom AJ, Lange A, Koele P, van Dyck R. Treatment of panic disorder with agoraphobia: comparison of fluvoxamine, placebo, and psychological panic management combined with exposure and of exposure in vivo alone. Am J Psychiatry 1995;152:683-91,
[12.] Sheehan DV, Harnett-Sheehan K. The role of SSRIs in panic disorder. J Clin Psychiatry 1996;57(Suppl 10): 51-8.
[13.] Lycliard RB, Ballenger JC. Panic-related disorders: evidence for efficacy of the antidepressants. Special issue: perspectives on panic-related disorders. J Anxiety Dis 1988;2:77-94.
[14.] Buigues J, Vallejo J. Therapeutic response to phenelzine in patients with panic disorder and agoraphobia with panic attacks. J Clin Psychiatry 1987;48:55-9.
[15.] Drug treatment of panic disorder. Comparative efficacy of alprazolam, imipramine, and placebo. Cross-National Collaborative Panic Study, Second Phase Investigators. Br J Psychiatry 1992;160:191-202 [published erratum appears in Br J Psychiatry 1992; 161:724].
[16.] Noyes R Jr, DuPont RL Jr, Pecknold JC, Rifkin A, Rubin RT Swinson RP, et al. Alprazolam in panic disorder and agoraphobia: results from a multicenter trial. II. Patient acceptance, side effects, and safety. Arch Gen Psychiatry 1988;45:423-8.
[17.] Davidson JR. Use of benzodiazepines in panic disorder. J Clin Psychiatry 1997;58(Suppl 2):26-8.
[18.] Owen RT, Tyrer P. Benzodiazepine dependence. A review of the evidence. Drugs 1983;25:385-98.
[19.] Spiegel DA, Bruce TJ, Gregg SF, Nuzzarello A. Does cognitive behavior therapy assist slow-taper alprazolam discontinuation in panic disorder? Am J Psychiatry 1994; 151:876-81.
[20.] Ballenger JC, Lycliard RB, Turner SM. Panic disorder and agoraphobia. In: Gabbard GO, ed. Treatments of psychiatric disorders. Vol 2. Washington, D.C.: American Psychiatric Press, 1995.
[21.] DeMartinis NA, Schweizer E, Rickels K. An open-label trial of nefazodone in high comorbidity panic disorder. J Clin Psychiatry 1996;57:245-8.
[22.] Geracioti TD Jr. Venlafaxine treatment of panic disorder: a case series. J Clin Psychiatry 1995;56:408-10.
[23.] Benjamin J, Levine J, Fux M, Aviv A, Levy D, Belmaker RH. Double-blind, placebo-controlled, crossover trial of inositol treatment for panic disorder. Am J Psychiatry 1995; 152:1084-6.
[24.] Charney DS, Woods SW, Goodman WK, Rifkin B, Kinch M, Aiken B, et al. Drug treatment of panic disorder: the comparative efficacy of imipramine, alprazolam, and trazodone. J Clin Psychiatry 1986-147: 580-6.
[25.] Mavissakalian M, Perel J, Bowler K, Dealy R. Trazodone in the treatment of panic disorder and agoraphobia with panic attacks. Am J Psychiatry 1987; 144:785-7.
[26.] Klein E, Uhde TW. Controlled study of verapamil for treatment of panic disorder. Am J Psychiatry 1988; 145:431-4.
[27.] Keck PE Jr, Taylor VE, Tugrul KC, McElroy SL, Bennett JA. Valproate treatment of panic disorder and lactate-induced panic attacks. Biol Psychiatry 1993133:542-6.
[28.] Boyer W. Serotonin uptake inhibitors are superior to imipramine and alprazolam in alleviating panic attacks: a meta-analysis. Int Clin Psychopharmacol 1995; 10:45-9.
[29.] Shear MK, Weiner K. Psychotherapy for panic disorder. J Clin Psychiatry 1997;58(Suppl 2):38-43.
[30.] Clark DM, Salkovskis PM, Hackmann A, Middleton H, Anastasiades P, Gelder M. A comparison of cognitive therapy, applied relaxation and imipramine in the treatment of panic disorder. Br J Psychiatry 1994; 164:7 59-69.
[31.] Barlow DH, Craske MG. Mastery of your anxiety and panic. II. Albany, N.Y.: Graywind, 1994.
[32.] Barlow DH. Cognitive-behavioral therapy for panic disorder: current status. J Clin Psychiatry 1997;58 (Suppl 2):32-6.
[33.] Gould RA, Otto MW, Pollack MH. A meta-analysis of treatment outcome for panic disorder. Clin Psych Rev 1995; 15:819-44.
[34.] Brown TA, Barlow DH. Long-term outcome in cognitive-behavioral treatment of panic disorder: clinical predictors and alternative strategies for assessment. J Consult Clin Psychol 1995;63:754-65.
[35.] Rosenbaum JF, Pollock RA, Jordan SK, Pollack MH. The pharmacotherapy of panic disorder. Bull Menninger Clin 1996;60(Suppl A)A54-75.
S. ATEZAZ SAEED, M.D., is acting chairman of the Department of Psychiatry and Behavioral Medicine and director of education in psychiatry at the University of Illinois College of Medicine at Peoria. He is also co-director of the Anxiety and Mood Disorders Clinic of the university. Dr. Saeed is a graduate of Dow Medical College, Karachi, Pakistan, and completed a residency in psychiatry at the Illinois State Psychiatric Institute, Chicago.
TIMOTHY J. BRUCE, PH.D., is assistant professor of psychology and director of undergraduate medical education at the University of Illinois College of Medicine at Peoria. He also is co-director of the Anxiety and Mood Disorders Clinic of the university. Dr. Bruce is a graduate of the State University of New York at Albany and completed a residency in clinical psychology at Wilford Hall USAF Medical Center, San Antonio, Tex.
Address correspondence to S. Atezaz Saeed, M.D., Acting Chairman, Department of Psychology and Behavioral Medicine, University of Illinois College of Medicine at Peoria, 7725 N. Knoxville Ave., Lower Level, Peoria, IL 61614. Reprints are not available from the authors.
COPYRIGHT 1998 American Academy of Family Physicians
COPYRIGHT 2000 Gale Group